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Tumor-specific genomic information has the poten-
tial to guide therapeutic strategies and revolutionize
patient treatment. Currently, this approach is limited
by an abundance of disease-associated mutants
whose biological functions and impacts on thera-
peutic response are uncharacterized. To begin to
address this limitation, we functionally characterized
nearly all (99.84%) missense mutants of MAPK1/
ERK2, an essential effector of oncogenic RAS and
RAF. Using this approach, we discovered rare gain-
and loss-of-function ERK2 mutants found in human
tumors, revealing that, in the context of this assay,
mutational frequency alone cannot identify all func-
tionally impactful mutants. Gain-of-function ERK2
mutants induced variable responses to RAF-, MEK-,
and ERK-directed therapies, providing a reference
for future treatment decisions. Tumor-associated
mutations spatially clustered in two ERK2 effector-
recruitment domains yet produced mutants with
opposite phenotypes. This approach articulates an
allele-characterization framework that can be scaled
to meet the goals of genome-guided oncology.
INTRODUCTION
Many thousands of tumor genomes have been sequenced to
deepen our understanding of the genetic basis of cancer and
to guide therapeutic strategies (Roychowdhury and Chinnaiyan,
2014). Computational approaches that identify significantly
mutated genes or detect mutational clusters within individual
genes have revealed the complex landscape of genetic alter-
ations in cancer (Weinstein et al., 2013; Hudson et al., 2010;
Kamburov et al., 2015; Lawrence et al., 2014; Niu et al.,
2016; Porta-Pardo and Godzik, 2014; Tamborero et al., 2013;Cell Rep
This is an open access article under the CC BY-NVogelstein et al., 2013). As a result, tumor-associated mutations
have been detected in nearly all human genes and the number of
uncharacterized mutations continues to rise (Lawrence et al.,
2014).
Characterizing tumor-associated variants of uncertain signifi-
cance (VUS) is imperative for druggable therapeutic targets
that lack genomic indicators of clinical response. For example,
ATP-competitive inhibitors of the Ser/Thr kinase MAPK1/ERK2
are in early stage clinical trials (Infante et al., 2015, J. Clin. Oncol.,
abstract). Tumor-sequencing studies have identified a single
mutational hotspot in ERK2 (ERK2E322K) and many VUS. How-
ever, the infeasibility of characterizing mutant proteins at
massive scale has precluded the identification of functionally im-
pactful ERK2 mutants. In addition, this limitation has prevented
the comprehensive association of mutants with response to
RAF-, MEK- and ERK- (MAPK-pathway) directed therapies.
To address the challenge of interpreting mutations in ERK2,
we employed saturation mutagenesis to comprehensively char-
acterize the activity and drug responsiveness of 6,810 ERK2
missense mutants. We identify rare ERK2 mutants found in hu-
man tumors that have gain- or loss-of-function activity and drive
differential responses to MAPK-pathway-directed therapies.
Collectively, this method provides a scalable framework for
mutant characterization that can be used to deepen our under-
standing of disease-associated mutants.
RESULTS
Generation of an ERK2 Mutant Library
To enable the functional characterization of all possible mis-
sense mutations in cancer-associated genes, we established
Mutagenesis by Integrated TilEs (MITE), a DNA-synthesis-based
approach optimized for use in mammalian cells (Melnikov et al.,
2014). We generated a pooled, virally delivered, doxycycline-
induced, cDNA expression library containing all 19 amino acid
substitutions at residues 2–360 of ERK2 (Figures 1A and S1A).
Massively parallel sequencing confirmed the presence of 6,810
of 6,821 possible (99.84%) ERK2 mutants in both plasmid DNAorts 17, 1171–1183, October 18, 2016 ª 2016 The Author(s). 1171
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Functional Characterization of
6,810 ERK2 Mutants
(A) A pooled-format proliferation screen in A375
cells to measure the functional impact of 6,810
MAPK1/ERK2 mutants.
(B) Heatmap of the enrichment/depletion of ERK2
mutants in a pooled assay in which the proliferation
of A375 cells serves as an indirect measure of ERK2
function. Data points represent the mean of four
biological replicates. Gray boxes identify wild-type
residues (see also Tables S1 and S2).
(C) The aggregate impact of amino acid sub-
stitutions on ERK2 function in A375 cells.
(D) Composite metric of ERK2 function when
mutated at each amino acid, based on mutant
enrichment/depletion in A375 cells.
See also Figures S1 and S2 and Tables S1, S2,
and S3.and in genomic DNA from transduced A375 cells (Figures S1B
and S1C). MITE produced a library with a 4.7-fold increase in
the abundance of ERK2mutants and improved variant represen-
tation relative to bacterial mutagenesis (Figures S1A and S1D).
Comprehensive Assessment of Mutant ERK2
Phenotypes
Most cancer-associated mutations are extraordinarily rare. As a
result, the functional impact of these mutations are unknown,
and their contribution to disease biology is poorly understood.
As an initial step toward disambiguating functionally impactful
ERK2 mutants from inert mutants, we sought to test the function
of all possible ERK2 point mutants and use these data to
comprehensively identify cancer-associated gain-of-function
(GOF) and loss-of-function (LOF) mutants. Testing the function
of many thousands of ERK2 variants requires scalable assays
that employ simple phenotypes to measure ERK2 function.1172 Cell Reports 17, 1171–1183, October 18, 2016Toward this goal, the A375 cell line is a
useful model for studying ERK2 function.
A375 cells harbor a BRAFV600E mutation
that leads to constitutive activation of
ERK1/2. In this context, ERK activity is ho-
meostatic and is required for sustained
proliferation. As a result, increases or de-
creases in ERK function affect A375 prolif-
eration. For example, treating A375 cells
with RAF, MEK, or ERK inhibitors reduces
ERK signaling and impairs cellular prolifer-
ation (Emery et al., 2009). However,
increased pathway activity also negatively
affects cellular proliferation. For instance,
expression of constitutively active BRAF,
MEK1, or wild-type ERK2 decreases cell
growth as a function of MAPK-pathway
output (Figure 1A) (Goetz et al., 2014). We
took advantage of this system to assess
the function of all 6,810 ERK2 point mu-
tants. We hypothesized that, in A375, cells
expressing GOF ERK2 mutants will prolif-erate slower than cells expressingwild-type ERK2, whereas cells
expressing LOF ERK2 mutants will proliferate faster than cells
expressing wild-type ERK2 (Figure 1A). Thus, in a pooled
competition assay, we predicted that LOF ERK2 mutants would
be enriched relative to those with wild-type activity, whereas
GOF mutants would be depleted.
We induced mutant library expression with doxycycline in
A375 cells and quantified the relative abundance of each mutant
after 96 hr via massively parallel sequencing (see Supplemental
Experimental Procedures; Figure S2A). Enrichment and deple-
tion of ERK2 variants was calculated relative to their initial abun-
dance in non-induced A375 (Figures 1B, S2B, and S2C; Table
S1). We predicted that LOF mutants would be enriched and
GOF mutants would be depleted in this assay. Consistent with
this notion, mutations expected to disrupt ERK2 protein function,
including charged (arginine, aspartate, glutamate, and lysine)
and rigid (proline) substitutions, were the most widely enriched
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Figure 2. Comprehensive Identification of
ERK2 Mutants that Induce Resistance to
ERK-Directed Kinase Inhibitors
(A) Heatmap displaying the normalized enrich-
ment/depletion of individual ERK2 mutants ex-
pressed in A375 cells in the presence of the ERK
inhibitors SCH772984 or VRT-11E. Data points
represent the mean of four to six biological repli-
cates. Gray boxes identify wild-type residues.
(B) Annotation of ERK2 amino acids that when
mutated confer resistance to VRT-11E (VRT, red),
SCH772984 (SCH, orange), or both inhibitors (S+V,
black) when expressed in A375 cells.
See also Figure S3 and Tables S1, S3, S4, and S5.across all ERK2 mutant proteins (Figure 1C). Additionally, vari-
ants encoding substitutions in functionally essential ERK2 pro-
tein domains, including a subset of residues in the ATP-binding
pocket, regulatory phosphorylation sites, the glycine-rich loop,
the catalytic loop, the activation loop, and the F-helix were uni-
versally enriched and captured a number of previously reported
LOF ERK2 mutants (Goetz et al., 2014; Madhani et al., 1997;
McReynolds et al., 2016; Shin et al., 2010) (Figures 1B and
S2D; Table S2). We generated a composite, phenotypic score
for each residue that summarizes the impact of ERK2 mutation
on phenotypic behavior. Briefly, we summed the log(2) enrich-
ment/depletion values for all substitutions across each aminoCell Repoacid and normalized them to that of the
most depleted residue. In total, we iden-
tify 37 ERK2 residues that, whenmutated,
lead to mutant enrichment greater than or
equal to Thr-185—an essential phosphor-
ylation site in the ERK2 active site (Table
S3). Moreover, substitutions at Lys-54,
the kinase-essential ‘‘active lysine’’
traditionally mutated to create kinase-
impaired ERK2 were also widely enriched
(albeit to varying degrees) collectively
suggesting that variant enrichment might
serve as a proxy for decreased ERK2 ac-
tivity (Figures 1B and S2E). However, we
cannot conclude that all mutants that un-
derwent enrichment are in fact LOF, as
depletion may arise as a consequence
of additional mechanisms.
To further test the hypothesis that pro-
liferative changes induced by a subset of
ERK2 mutants may reflect altered ERK2
function, we asked whether mutation of
highly conserved ERK2 residues were en-
riched in our assay. To do this, we gener-
ated a cumulative phenotypic score for
each ERK2 residue by summing the log2
depletion/enrichment of all substitutions
at each amino acid and normalizing this
value to the residue with the highest cu-
mulative depletion (Figures 1D and S2E;
Table S3). We observed that substitutionsin highly conserved residues of ERK2 homologs have a signifi-
cantly greater propensity to be enriched and have a low pheno-
typic score (and therefore may be damaging) compared to sub-
stitutions in lowly conserved residues (Figure S2F). Expression of
ERK2mutants found in the germlines of healthy individuals—and
therefore expected to be inert—were neither enriched nor
depleted (ExAC, 2015) (Figure S2G). Moreover, we found that
mutations in internally buried residues presumed to maintain
ERK2 structure were enriched (Figure S2D). Collectively, these
observations suggested that variant enrichment may serve as
a proxy for reduced ERK2 activity and can rediscover previously
characterized ERK2 functional domains.rts 17, 1171–1183, October 18, 2016 1173
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A number of catalytically active ERK2 mutants have been pre-
viously identified (Bott et al., 1994; Chu et al., 1996; Emrick et al.,
2001, 2006; Goetz et al., 2014; Levin-Salomon et al., 2008, 2009;
Robinson et al., 1998; Shin et al., 2010; Smorodinsky-Atias et al.,
2016) (Table S2). However, the identification of tumor-associ-
ated ERK2 mutants with GOF in-cell phenotypes has remained
elusive in spite of the prevalence of constitutively active onco-
genic missense mutants in upstream pathway members,
including Ras-family members, BRAF, and MEK1/2 that signal
through ERK1/2 (Roskoski, 2012). Only a small subset of GOF
ERK2 mutants, including the sevenmaker mutation (human
ERK2D321N) and ERK2E322K has been found in human tumors
or cancer cell lines (Bott et al., 1994; Chu et al., 1996; Goetz
et al., 2014). We observed extensive depletion of previously
identified ERK2 GOF mutants in our assay (Table S2). For
example, Glu-322 and Asp-321 exhibited high phenotypic
scores and were 11th and 19th, respectively, of all 360 ERK2
amino acids ranked from most depleted (#1) to least depleted
(#360) (Figures 1D and S2E; Table S3). In addition, we found
an additional 19 mutant ERK2 residues that were depleted to a
degree equivalent to or greater than that of Glu-322 and Asp-
321 (Figure S2E; Table S3). The observation that previously char-
acterized GOF ERK2 mutants are depleted in this assay sug-
gests (but does not prove) that a subset of uncharacterized,
highly depleted ERK2 mutants may also be GOF. However, until
a comprehensive validation of all such mutants is complete, we
cannot conclude that all such mutants are in fact GOF, nor that
they have increased catalytic activity. These data raise the pos-
sibility that comprehensive approaches can be employed to
discover additional, cancer-associated mutants for deeper vali-
dation. In addition, a complete mapping of residues required for
normal ERK2 function may ultimately be useful for the design of
allosteric ERK2 inhibitors.
Comprehensive Identification of ERK-Inhibitor-
Resistant ERK2 Mutants
Guiding treatment strategies with tumor-specific genomic data
requires an understanding of how each mutant impacts res-
ponse to cancer therapeutics. Thus, we wished to discover all
possible ERK2 point mutants that could confer resistance to
ERK-directed small molecule inhibitors. In BRAFV600E mutant
melanoma cell lines, exposure to small-molecule ERK inhibitorsFigure 3. Spatial Mapping of ERK2 Mutants that Induce Resistance to
(A) Projection of ERK2mutant enrichment in A375 cells in the presence of VRT-11E
respectively). All mutants displaying a log(2) fold change ofR2 are represented. B
are shown in blue.
(B) Venn diagram highlighting the overlap of ERK2 residues that, when mutated, co
SCH772984.
(C) Structural representation of ERK2 residues that, whenmutated, confer resistan
and sized as in (A).
(D) Structural representation of ERK2 residues that, when mutated, confer resista
acid-adenylate ester (ANP) is shown in blue, MAPK-docking peptide is not show
(E) Structural representation of ERK2 residues that, when mutated, confer resista
colored and sized as in (A).
(F) Venn diagram highlighting the overlap of VRT-11E-specific residues with resi
(G) Venn diagram highlighting the overlap of VRT-11E/SCH772984-specific resid
(H) Venn diagram highlighting the overlap of VRT-11E-specific residues with resi
See also Figures S3 and S4 and Tables S1, S3, S4, and S5.suppresses proliferation. However, this phenotype can be res-
cued by restoring MAPK signaling to baseline levels by express-
ing drug-resistant ERK2 mutants (Figure 1A) (Goetz et al., 2014).
By performing these experiments in the presence of ERK2 inhib-
itors, and therefore in a background of reduced ERK activity and
cell proliferation, expression of drug-resistant ERK2 mutants are
sufficient to restore ERK signaling and rescue cell proliferation.
To discover ERK2 mutants that are resistant to ERK inhibitors,
we induced expression of mutant ERK2 proteins in BRAFV600E
mutant A375 cells and exposed them to sub-lethal doses of
two small molecule ERK1/2 kinase inhibitors, VRT-11E or
SCH772984 (Aronov et al., 2009;Morris et al., 2013) (Figure S3A).
After 12 days of drug exposure, enrichment of ERK2 mutants
was quantified relative to initial populations (Figures S3B and
S3C). Themajority of ERK2mutants were depleted from the pop-
ulation when exposed to drug (Figures S3B and S3C). The obser-
vation that most ERK2 mutants were depleted is a result of
calculating the ratio of ERK2 mutants exposed to drug relative
to their initial abundance prior to drug exposure.
We considered ERK2 variants that were enriched 4-fold or
greater (p% 0.025) in drug to be candidate resistance mutants.
We identified134substitutions in 30 residues that conferred resis-
tance to VRT-11E and 105 mutants in 36 residues that conferred
resistance to SCH772984 (Figure 2A; Table S4). Among these, 59
substitutions in 18 residues conferred resistance tobothVRT-11E
and SCH772984 (Figure 2B; Table S4). We recovered all of the
ERK2 variants previously discovered using traditional muta-
genesis approaches but increased ERK2 drug-resistant mutant
discovery by 15- to 19-fold (Goetz et al., 2014). Surprisingly, resis-
tance-conferring events were uncorrelated with ERK2 enrich-
ment/depletion in the absence of ERK inhibition (Table S3).
We identified resistance mutants that map to residues in the
ATP binding pocket (Figures 2A and 3A). However, we also found
drug-resistant mutants in other ERK2 protein domains, including
substitutions in the aL16-helix (ERK2
I347W, ERK2I347Y), the DFG
motif (ERK2G169D), and mutations in uncharacterized regions of
ERK2, including ERK2R15P, ERK2D124T, ERK2C127I, and 11 sub-
stitutions at Pro-58 (Figures 2A and 3A). A single mutation in
the MAPK3/ERK1 DFG motif (ERK1G186D) was recently discov-
ered in a SCH772984-resistant mutagenic cell line (Jha et al.,
2016). Encouragingly, we found that a G / D substitution at
the orthologous residue in ERK2 (ERK2G169D) was the onlyERK-Directed Kinase Inhibitors
or SCH772984 on the structure of drug-bound ERK2 (PDB ID: 4QTE and 4QTA,
lue lines identify intramolecular contacts between ERK2 and inhibitor. Inhibitors
nfer resistance to either VRT-11E only, SCH772984 only, or both VRT-11E and
ce to VRT-11E (PDB ID: 4QTE). VRT-11E is shown in blue; residues are colored
nce to VRT-11E and SCH772984 (PDB ID: 4FMQ). Phosphoaminophosphonic
n; residues are colored and sized as in (A).
nce to SCH772984 (PDB ID: 4QTE). SCH772984 is shown in blue, residues are
dues that form direct contacts with VRT-11E.
ues with residues that form direct contacts with both inhibitors.
dues that form direct contacts with SCH772984.
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alteration at Gly-169 sufficient to induce resistance to ERK
inhibitors (Figures 2A and 2B).
Given the propensity for resistance mutations to arise in drug
targets during the course of treatment, a comprehensive catalog
of resistance mutants to mechanistically distinct inhibitors may
guide the choice of therapies at relapse. To identify inhibitor-
specific resistance mutants, we looked for ERK2 mutants that
drove resistance to either VRT-11E or SCH772984 (fold change
R4) but additionally had a differential fold enrichment between
inhibitors of 4-fold or greater. We identified 66 mutants that
uniquely confer resistance to VRT-11E and 24 mutants that
uniquely confer resistance to SCH772984 (Figures 2B and
S3D; Table S4). When mutated, only a subset of amino acids
conferred mutually exclusive drug resistance to VRT-11E (12
residues) or SCH772984 (nine residues), whereas mutation of
18 residues conferred resistance to both small molecules (Fig-
ures 3B–3E; Table S5).While 50%of the ERK2 VRT-11E-specific
resistance residues make direct contacts with VRT-11E, none of
the SCH772984-specific ERK2 resistance residues make direct
contact with SCH772984 (Figures 3F–3H; Table S6). Collectively,
these observations suggest that drug-specific resistance alter-
ations cannot be fully explained by direct drug-protein interac-
tions alone. In the aggregate, these efforts have revealed an un-
appreciated diversity of ERK2 drug-resistant mutants that may
ultimately guide the choice of therapy at initial diagnosis or
relapse.
Massively Parallel Characterization of ERK2 Mutants
Found in Human Tumors
Sequencing of many thousands of human tumors has revealed
the landscape of genetic variation across cancer. However,
disambiguating inert mutations frommutations that are function-
ally impactful remains a challenge. Guided by the rediscovery of
mutants known to impact ERK2 function, we sought to identify
unappreciated, functionally relevant, cancer-associated ERK2
mutants with the ultimate goal of informing initial therapeutic
strategies in patients whose tumors harbor these mutants. To
do this, we aggregated all tumor-associated ERK2 mutations
from The Cancer Genome Atlas, the Catalogue Of Somatic
Mutations In Cancer or individual sequencing studies (Figure 4A;
Table S7), identifying 83 unique missense mutations or small
insertion/deletions in ERK2 (Cerami et al., 2012; Forbes et al.,
2015; Gao et al., 2013; Ojesina et al., 2014). We then projected
our phenotypic data onto these cancer-associated mutants
and identified those that were depleted in our screen (Figure 4A).
Using our composite ERK2 phenotypic score, we ranked all 359
ERK2 residues from most depleted (#1) to most enriched (#359).
Within the top 20 most depleted ERK2 residues, we found
five ERK2 residues that contain missense mutations observed(C) Suppression of A375 proliferation with 2 nM trametinib (Tra, 96 hr of treatmen
mean (±SD) of at least six replicates.
(D) Suppression of A375 proliferation with 500 nM SCH772984 (SCH, 96 hr of
represented as a mean (±SD) of at least six replicates.
(E) In vitro kinase assay using V5-tagged ERK2 mutants immunoprecipitated fro
determined by the capacity to phosphorylate purified ELK1 (pERK, phosphorylat
kinase assay).
See also Figures S2 and S4 and Tables S1, S2, S3, and S7.in patient tumors or tumor-derived cell lines, including ERK2E322K
(n = 19), ERK2E322V (n = 1), ERK2D321N (n = 2), ERK2D321V (n = 1),
ERK2E81K (n = 2), ERK2P58L (n = 1), and ERK2S142L (n = 1) (Figures
4A and S2E). Collectively, these five ERK2 residues contain 32%
(27/84) of all observed ERK2 cancer-associated mutants, none
of which have yet to be found in the germline of healthy patients
(ExAC, 2015). Many ERK2 cancer-associated mutants are
observed in only a single patient and would be missed by
frequency-based methods. Among these somatic events, sub-
stitutions at Pro-58 were associated with a drug-resistance
phenotype (Figures 2A, 3A, and S3E). These data highlight
the capacity of comprehensive variant characterization to
nominate unappreciated candidate GOF mutants for subse-
quent validation.
Mutational frequency is often used to nominate oncogenic,
activating somatic mutations. However, recurrent ERK2 muta-
tions were not universally depleted in A375. For example, Arg-
191 is recurrently mutated to His/Cys in ERK2 (n = 3). However,
in this phenotypic assay, mutation of Arg-191was as enriched as
mutation of the kinase-essential phosphorylation sites Thr-185/
Tyr-187 or the active lysine (Lys-54) (Figure S2E). In fact, somatic
variants that encode enriched ERK2 proteins are not uncommon:
we identified a number of ERK2 mutants that are enriched and
disrupt highly conserved ERK2 residues previously character-
ized as critical for ATP binding or ERK2 activation but have not
been observed in the germline of healthy humans, including
ERK2T185A (n = 1), ERK2D167E/G (n = 2), ERK2D149Y (n = 1),
ERK2R148L/S (n = 2), and ERK2H147Y (n = 1). These data sug-
gested that, in the contextual constraints of this assay, a subset
of enriched, tumor-associated ERK2 mutants may be kinase
impaired, highlighting the need for functional approaches to
complement frequency-based computational methods.
Validation of Candidate GOF or LOF ERK2 Mutants
High-throughput assays permit comprehensive characterization
of mutant behavior in simple assays (e.g., enrichment/depletion)
but are not optimized to the nuances of each mutant and cannot
identify more complex phenotypes (e.g., GOF/LOF) a priori.
As such, validation of presumed mutant function is critical
if we wish to interpret the consequences of mutant function
and/or use this information to guide patient treatment strategies.
ERK2 mutants with presumed GOF activity should retain func-
tion in the context of limited upstream MAPK-pathway activity.
Thus, candidate ERK2 GOF mutants should rescue the pro-
liferative effects of RAF or MEK inhibition, whereas mutants
with wild-type or LOF activity should not. To test our functional
predictions of ERK2 mutants found both in (1) human tumors
and (2) displaying depletion/enrichment phenotypes in our
screen, we expressed ERK2 mutants in A375 cells and testedt) and proliferative rescue with GOF ERK2 mutants. Data are represented as a
treatment) and proliferative rescue with ERK2 resistance mutants. Data are
m A375 cells treated with DMSO or 4 nM trametinib for 4 hr. Kinase activity is
ed ERK; VINC, vinculin; V5 IP KA, immunoprecipitated V5 epitope followed by
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their response to inhibitors of RAF or MEK (Figures 4B and
4C). Expression of wild-type ERK2, kinase-impaired ERK2
(ERK2K54R), and candidate LOF mutants (ERK2R191H and
ERK2T185A) were insufficient to rescue the anti-proliferative ef-
fects of RAF or MEK inhibitors (Figures 4B and 4C). In contrast,
putative GOF mutant ERK2 proteins (ERK2E322K, ERK2E322V,
ERK2D321N, ERK2D321V, ERK2E81K, and ERK2S142L) all restored
cell proliferation to levels comparable to cells expressing consti-
tutively active MEK1 (MEK1S218/222D or MEK1DD) or ectopic
BRAFV600E (Figures 4B and 4C). Only two ERK2 mutants tested
here, ERK2P58L and ERK2P58G, were able to confer ERK-inhibitor
resistance (Figures 4D and S3E). ERK2P58L had amodest capac-
ity to rescue RAF inhibition, whereas other substitutions at the
same Pro-58 residue, including ERK2P58G, had more prominent
phenotypes (Figures 4B and 4C). Consistent with these data, im-
munoprecipitates from candidate GOF ERK2 mutants were able
to induce a mobility shift of recombinant ELK1 (a surrogate for
ELK1 phosphorylation) in vitro following treatment with trameti-
nib at a concentration that suppressed wild-type ERK2 activity
(Figure 4E). In this assay, the candidate LOF mutants, including
ERK2R191H and kinase-dead ERK2K54R, were unable to induce
ELK1 phosphorylation or mobility shift at baseline or in the pres-
ence of trametinib (Figures 4E and S4A).These data suggested
that a subset of ERK2 somatic mutants possess GOF activity
and that RAF and MEK inhibitors may be contraindicated for pa-
tients whose tumors harbor these mutants. Moreover, in spite of
their contextual limitations, these studies demonstrate that high-
throughput approaches can identify unappreciated GOF and
LOF mutants found in human tumors.
Spatially Proximal ERK2MutationsEncodeMutantswith
Opposite Phenotypes
Computational approaches have dramatically improved our abil-
ity to identify functionally impactful cancer-associated mutants
(Kamburov et al., 2015; Lawrence et al., 2014; Porta-Pardo
and Godzik, 2014; Tamborero et al., 2013; Vogelstein et al.,
2013). These approaches identified a ‘‘hotspot’’ mutation in
ERK2 (E322K) that displays GOF properties in validation experi-
ments (Figures 4B, 4C, and 4E). Orthogonal computational ap-
proaches, including CLUMPS, additionally identified enrichment
(p = 0.0053) of mutant residues (including E322K) within ERK2
effector recruitment domains (Alexa et al., 2015; Kamburov
et al., 2015; Lawrence et al., 2014). This observation was
buttressed by the finding that additional ERK2 tumor-associated
mutations not found within the CLUMPS mutational search
space were are also enriched (p = 4.303 3 105, Fisher’s exact
test) in ERK2 effector recruitment domains (Figure 5A) (Lee(B) Alteration of residues in the DRS of ERK2 are associated with GOF phenotyp
(p = 2.13 3 107, Student’s t test). Data points represent the mean of four biologi
(C) Western blot of lysates from A375 cells showing that ERK2 DRS mutants in
ERK2K54R or the phosphorylation site (p-site) mutants ERK2T185A ERK2T187A (pER
(D) ERK2 DRSmutants rescue the anti-proliferative effects of trametinib in A375 ce
as a mean (±SD) of at least six replicates.
(E) Compound mutation of the FRS (Y233A) in ERK2 DRS mutants abrogate th
treatment) in A375 cells. Data are represented as a mean (±SD) of at least six re
(F) Western blot showing that compound mutation of the FRS (Y233A) in DRS ER
cells.
See also Figure S5 and Table S3.et al., 2004; Zhang et al., 2003). While these approaches univer-
sally nominated ERK2 recruitment domain mutants as function-
ally important, we were surprised to observe that both depleted
and enriched ERK2 mutants, including validated ERK2 GOF and
LOFmutants, clustered inERK2 recruitment domains (Figure 5A).
This phenotypic distinction was not random: mutant activity was
dictated by their localization within two distinct, well-character-
ized recruitment regions; alterations in the D-recruitment site
(DRS, alternatively known as the common docking domain)
contained both depleted and validated GOF proteins, whereas
alterations in the F-recruitment site (FRS, alternately known as
the DEF [docking site for ERK and FXFP] pocket) encoded en-
riched and validated LOF proteins (Roskoski, 2012) (Figures 5B
and S5A).
To validate the hypothesis that FRS mutants are LOF and
that DRS mutants are GOF, we expressed ERK2 domain mu-
tants in A375 cells and exposed them to the MEK inhibitor tra-
metinib. DRS mutants displayed an increased capacity to
phosphorylate downstream pathway components (Figure 5C)
and could rescue the proliferative decrement caused by
MEK inhibition (Figure 5D). In contrast, ERK2 FRS mutants
behaved equivalently to kinase-impaired ERK2 (ERK2K54R),
were unable to signal to DUSP6, FOS, and FRA1 (Figures 5C
and S5B), and could not rescue the anti-proliferative effects
of MEK inhibition (Figure 5D). Compound mutation of the
FRS (ERK2Y233A) in DRS mutants abrogated their capacity to
rescue upstream MEK inhibition and curtailed downstream
signaling to DUSP6, FOS, and FRA1 similar to kinase-impaired
ERK2 (ERK2K54R), suggesting that an intact FRS is required for
GOF DRS mutants (Figures 5E and 5F). Given the proximity of
the FRS to the activation loop and catalytic residues, it is likely
that mutations in the FRS would negatively impact ERK2 ki-
nase activity. Consistent with this prediction, FRS LOF ERK2
mutants have no activity in vitro (Figures 4E and S4A).Thus,
although ERK2 mutations found in human tumors frequently
cluster within ERK2 recruitment sites, they produce proteins
with opposing phenotypes.
Tumor-Associated ERK2 DRSMutants Are Refractory to
Dephosphorylation by DUSP6
High-throughput approaches can identify GOF mutants with
equivalent phenotypes. However, determining themechanism(s)
of GOF mutants remains a challenge. ERK2D321N was originally
discovered as a GOF mutant that has sustained kinase activity
resulting from disrupted negative regulation by the DUSP6 phos-
phatase—an ERK2 effector that inhibits ERK2 activity through
direct dephosphorylation (Bott et al., 1994; Chu et al., 1996;es, whereas alterations in FRS residues are associated with LOF phenotypes
cal replicates in A375 cells.
duce DUSP6 expression, whereas FRS mutants behave like kinase impaired
K, phosphorylated ERK; VINC, vinculin).
lls (Tra, 96 hr of treatment), whereas FRSmutants do not. Data are represented
eir capacity to rescue the anti-proliferative effects of trametinib (Tra, 96 hr of
plicates.
K2 mutants abrogate their capacity to signal to downstream effectors in A375
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Figure 6. Somatic DRS ERK2 Mutants Are
Refractory to De-phosphorylation by the
DUSP6 Phosphatase
(A) Somatically mutated residues in the DRS of
ERK2 (blue) form direct contacts with ERK2
effectors, including RSK1 (green, PDB ID: 4NIF).
(B) Somatic DRS ERK2 mutants are refractory to
dephosphorylation by the DUSP6 phosphatase in
transfected HEK293T cells (pERK, phosphorylated
ERK; VINC, vinculin).
(C) Quantification of phosphorylated mutant ERK2
when co-expressed with DUSP6, as in (B). Data
are represented as the mean (±SD) from three in-
dependent experiments in HEK293T cells. Values
are normalized to wild-type ERK2.Li et al., 2007). As DUSP6 interacts with ERK2 via the DRS, we
hypothesized that disrupted negative regulation by DUSP6
may represent a generalizable mechanism for ERK2 DRS GOF
properties (Farooq et al., 2001). This hypothesis was supported
by the observation that ERK2E322, ERK2D321, and ERK2E81
establish the charged surface of the ERK2 DRS and form direct
contacts with ERK2 effectors (Figure 6A).
To test this hypothesis, we co-expressed ERK2 mutants
with BRAFV600E and either eGFP or DUSP6 in 293T cells1180 Cell Reports 17, 1171–1183, October 18, 2016and measured ERK2 phosphorylation.
Co-expression of DUSP6 abrogated
phosphorylation of wild-type ERK2,
kinase-impaired ERK2 (ERK2K54R),
ERK2R191H, and endogenous ERK2 (Fig-
ures 6B and 6C). In contrast, DRS mu-
tants all displayed sustained ERK2
phosphorylation in the presence of
ectopic DUSP6. Surprisingly, ERK2S142L
showed an equivalent degree of sus-
tained phosphorylation when compared
to known DRS ERK2 mutants, suggest-
ing that impaired dephosphorylation by
DUSP6 might underlie the GOF proper-
ties of DRS mutants and ERK2S142L.
Given the physical proximity of Ser-
142 to the DRS, these data suggest
that Ser-142 may be an unappreciated
component of the ERK2 DRS (Fig-
ure S5C). Notably, sustained phosphor-
ylation was not a universal property of
GOF ERK2 mutants—ERK2P58L ex-
hibited a marked reduction in phos-
phorylation in the presence of DUSP6
(Figures 6B and 6C). Collectively, these
studies suggest that rare cancer mu-
tants, such as ERK2E81K, ERK2S142L,
and ERK2D321N, can achieve GOF prop-
erties through the same mechanisms as
recurrent alterations (ERK2E322K). These
observations are corroborated by the
fact that ERK2 mutants that abrogate
DUSP6 dephosphorylation are rarelyfound in tumors that simultaneously contain alterations lead-
ing to frank MAPK pathway activation—in this context, there
would be little preference for ERK2 mutations that impede
ERK2 phosphorylation.
DISCUSSION
Comprehensive saturation mutagenesis has set the stage for
mutant protein characterization at scale. We applied these
technological advances to characterize mutants of ERK2 and
identified a number of functionally consequential ERK2 mutants
found in human tumors, including rare GOF ERK2 mutants. We
also identified recurrent LOF ERK2 mutants, potentially indi-
cating that these mutants can confer a selection advantage in
certain contexts or possess kinase-activity-independent func-
tions for ERK2 (Rodrı´guez and Crespo, 2011). Although it re-
mains to be determined whether GOF or LOF alterations impact
tumorigenesis or engender a dependency on ERK signaling in
tumors, these data raise the possibility that presumed onco-
genes can have both GOF or LOF mutations and challenge the
gene-centric paradigm in which the classification of cancer
genes is driven by the functions of a few deeply studied mutants.
Moreover, these results imply that the mutational frequency of
individual mutants is not a universal predictor of mutant protein
function.
Collectively, these efforts represent an initial step toward
comprehensive genome-guided oncology and suggest a general
framework for disease-associated mutant classification. As
genome sequencing studies multiply, these data remain stable
and can continue to serve as a reference for newly discovered
mutations. Moreover, as a resource, this library (and future li-
braries) can be publically deployed in multiple assays and
cellular lineages to identify context-specific mutant function
not feasible in these initial studies (Kim et al., 2016; Berger et.
al., 2016). Moving forward, one could imagine public repositories
of aggregated somatic mutations alongside comprehensive
phenotypic annotation.
The sevenmaker mutation (ERK2D321N) was discovered in
D. melanogaster over 20 years ago and has been extensively
characterized as a GOF mutant. However, since its discovery,
the sevenmaker mutation has rarely been found in human
tumors and, as a consequence, its role in oncology has re-
mained unappreciated. Here, we identify additional cancer-
associated GOF ERK2 mutants that mechanistically copy the
sevenmaker mechanism of activation, are refractory to nega-
tive regulation by DUSP-family phosphatases, and lead to
sustained ERK2 function in the presence of limiting upstream
MEK activation. Thus, while the sevenmaker mutant itself
is quite rare in human tumors, the discovery of additional
‘‘sevenmaker-like’’ mutants suggests that an unexpectedly
large fraction of all cancer associated ERK2 mutants utilize
similar mechanisms of activation, supporting a larger-than-
appreciated role for the sevenmaker mutant in cancer. In
contrast, we observed that alterations at Pro-58 achieve
equivalent GOF phenotypes through mechanistically distinct
mechanisms, despite the fact that this mutant has only been
observed in a single patient sample.
Our comprehensive, unbiased approach to annotating
ERK2 mutants allowed us to uncover unappreciated GOF
or LOF somatic missense mutations in a heavily investigated
gene and signaling pathway whose activation is long appre-
ciated in cancer. These studies illustrate the potential of
comprehensive mutant-characterization strategies to accel-
erate GOF mutant discovery, preemptively identify drug-
resistant mutants, deepen our understanding of gene-regula-
tory mechanisms, and clarify how their disruption contributes
to tumorigenesis.EXPERIMENTAL PROCEDURES
High-Throughput ERK2 Mutant Screens
A375 cells were infected in six biological replicates (5.1 3 107 cells/replicate,
19% infection efficiency) with the lentiviral ERK2mutant library followed by se-
lection with puromycin. Post selection, we achieved an allelic representation of
1171–1482 cells per variant. Each replicate was split into four experimental
arms: (1) 24-hr un-induced early time point, (2) 96 hr of 1 mg/ml doxycycline
and 16 hr of 1 mg/ml doxycycline followed by treatment with (3) 2 mM
SCH772984 or (4) 3 mM VRT11E for 12 days of continuous culture. Genomic
DNA was prepared from cell pellets (2.0 3 107 cells/replicate) and treated
with RNase and ERK2 variants amplified with vector-specific primers (for-
ward: TGGGAGGCCTATATAAGCAGAGCTCG, reverse: CGGAACCACGCCC
AGAGC). Indexed Nextera libraries were generated from PCR products and
subjected to massively parallel sequencing on four lanes of HighSeq2500, re-
sulting in a minimum of 200 million reads per lane and an average coverage of
0.33 per sample. ERK2 protein structures were all retrieved from PDB: 4NIF,
2ERK, 4QTE, 4QTA, and 4FMQ. Mapping of phenotypic data onto the crystal
structure of ERK2 was performed using UCSF Chimera (Pettersen et al., 2004).
Creation of Individual ERK2 Mutants
Full-length wild-type ERK2 (NM_002745.4) was synthesized (GenScript), and
site-directed mutagenesis was performed in pDONOR223 to all reported
ERK2 mutants. All mutants were sequence confirmed using Sanger
sequencing and transferred by LR-mediated recombination into the lentiviral
vectors pLiX403 (Addgene) for inducible gene expression or pLVX307 (Addg-
ene) for constitutive expression in mammalian cells.
Drug-Sensitivity Measurements
Inducible ERK2 mutant-expressing A375 cells were seeded into 96-well,
white-walled, clear-bottom plates at a density of 2500 cells/well. Twenty-
four hours after seeding, doxycycline was added to the wells at a concentra-
tion of 1 mg/ml, and drugs were added using an HP D300 Digital Dispenser
at the following concentrations: trametinib at 2 nM, SCH722984 at 500 nM,
and dabrafenib at 10 nM, with the final volume of DMSO not exceeding
0.5%. After the addition of drugs, cells were incubated for 96 hr, and cell
viability was measured using CellTiterGlo viability assay (Promega). Viability
was calculated as a percentage of control (DMSO-treated A375 cells with
1 mg/ml doxycycline). A minimum of six replicates were performed for each
independent experiment.
Immunoblots
Adherent cells were washed once with ice-cold PBS and lysed with 1% NP-
40 buffer (150 mMNaCl, 50 mM Tris [pH 7.5], 2 mM EDTA [pH 8], 25 mMNaF,
and 1% NP-40) containing 2 3 protease inhibitors (Roche) and 1 3 Phos-
phatase Inhibitor Cocktails I and II (Calbiochem). Lysate protein content
was quantified (BCA assay) and normalized, and then proteins were reduced
and denatured (95C) and resolved by SDS gel electrophoresis on 4%–20%
Tris/Glycine gels (Invitrogen). Resolved protein was transferred to nitrocellu-
lose membranes, blocked in LiCOR blocking buffer and probed with primary
antibodies.
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